Triazolam
 | |
 | |
| Klinički podaci | |
|---|---|
| Prodajno ime | Alti-Triazolam, Apo-Triazo, Clorazolam, Gen-Triazolam |
| Drugs.com | Monografija |
| Način primene | Oralno |
| Farmakokinetički podaci | |
| Poluvreme eliminacije | 1,5-5,5 h |
| Identifikatori | |
| CAS broj | 28911-01-5  |
| ATC kod | N05CD05 (WHO) |
| PubChem | CID 5556 |
| DrugBank | DB00897 |
| ChemSpider | 5355 |
| ChEBI | CHEBI:9674 |
| ChEMBL | CHEMBL646 |
| Hemijski podaci | |
| Formula | C17H12Cl2N4 |
| Molarna masa | 343,210 |
| |
| |
| Fizički podaci | |
| Tačka topljenja | 233—235 °C (451—455 °F) |
Triazolam je organsko jedinjenje, koje sadrži 17 atoma ugljenika i ima molekulsku masu od 343,210 Da.[1][2][3][4][5][6][7]
Osobine
[уреди | уреди извор]| Osobina | Vrednost |
|---|---|
| Broj akceptora vodonika | 3 |
| Broj donora vodonika | 0 |
| Broj rotacionih veza | 1 |
| Particioni koeficijent[8] (ALogP) | 4,2 |
| Rastvorljivost[9] (logS, log(mol/L)) | -6,6 |
| Polarna površina[10] (PSA, Å2) | 43,1 |
Reference
[уреди | уреди извор]- ^ Rickels K. „The clinical use of hypnotics: indications for use and the need for a variety of hypnotics”. Acta Psychiatr Scand Suppl. 1986 (332): 132—41. PMID 2883820.
- ^ Oelschläger, H. (1989). „Chemical and pharmacologic aspects of benzodiazepines”. Schweizerische Rundschau Fur Medizin Praxis = Revue Suisse de Medecine Praxis. 78 (27–28): 766—772. PMID 2570451.
- ^ Noguchi H, Kitazumi K, Mori M, Shiba T (март 2004). „Electroencephalographic properties of zaleplon, a non-benzodiazepine sedative/hypnotic, in rats”. J Pharmacol Sci. 94 (3): 246—51. PMID 15037809.
- ^ Tokunaga S, Takeda Y, Shinomiya K, Hirase M, Kamei C (фебруар 2007). „Effects of some H1-antagonists on the sleep-wake cycle in sleep-disturbed rats”. J Pharmacol Sci. 103 (2): 201—6. PMID 17287588.
- ^ Veje, J. O.; Andersen, K.; Gjesing, S.; Kielgast, H. (август 1989). „Prescription of tranquilizers and hypnotics in the municipality of Holbaek”. Ugeskr Laeger. 151 (34): 2134—6. PMID 2773144.
- ^ Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011). „DrugBank 3.0: A comprehensive resource for 'omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—41. PMC 3013709
. PMID 21059682. doi:10.1093/nar/gkq1126.
- ^ Wishart, D. S.; Knox, C.; Guo, A. C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. (2008). „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.
- ^ Ghose, Arup K.; Viswanadhan, Vellarkad N.; Wendoloski, John J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods”. The Journal of Physical Chemistry A. 102 (21): 3762—3772. Bibcode:1998JPCA..102.3762G. doi:10.1021/jp980230o.
- ^ Tetko, I. V.; Tanchuk, V. Y.; Kasheva, T. N.; Villa, A. E. (2001). „Estimation of aqueous solubility of chemical compounds using E-state indices”. Journal of Chemical Information and Computer Sciences. 41 (6): 1488—1493. PMID 11749573. doi:10.1021/ci000392t.
- ^ Ertl, P.; Rohde, B.; Selzer, P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties”. Journal of Medicinal Chemistry. 43 (20): 3714—3717. PMID 11020286. doi:10.1021/jm000942e.
Literatura
[уреди | уреди извор]- Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
- Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.
Spoljašnje veze
[уреди | уреди извор]
 | Molimo Vas, obratite pažnju na važno upozorenje u vezi sa temama iz oblasti medicine (zdravlja). |
